EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs
Conferences and next Working Groups
- 6 May 2015: EUCOPE Pharmacovigilance/Regulatory Working Group Meeting in Brussels
- 11 May 2015: EUCOPE Orphan Medicinal Products Working Group Meeting in Brussels
- 11 May 2015: EUCOPE/EMIG Legal Meeting in London
- 12 June 2015: EUCOPE Pricing & Reimbursement / Market Access Working Group Meeting in Brussels
- 30 June 2015: EUCOPE Board Meeting and General Meeting in Brussels
- 7 September 2015: EUCOPE/EMIG Legal Meeting in London
- 14 October 2015: EUCOPE Board Meeting in Brussels
- 9 November 2015: EUCOPE/EMIG Legal Meeting in London
European Biotechnology – A Medical Focus
EUCOPE is proud to be part of the 2014 publication “European Biotechnology – A Medical Focus” by Horn Publishing. Alexander Natz has contributed with a foreword on the Impact of Clinical Trial Data Transparency for Biotechnology in Europe. An online version of the publication can be found here.
Life Sciences College
13 May 2015 in London
During this one-day program, sessions will cover recent developments in the areas of EU data privacy, antitrust, anti-corruption, regulatory, compliance, enforcement, corporate transactions and arbitration.
This year’s event will feature prominent speakers from healthcare and competition regulators, including from the European Commission, EDPS, national authorities and representatives from the pharmaceutical industry. More information on the event held in London on 13 May can be found here.
Eye on Bio
9 June 2015 in London
Biotech Investment: Have the UK and Europe come of age? At this half-day conference, the opportunities and challenges of investing in biotech in the UK and Europe will be explored, focusing on the following topics: Regulatory strategy as a business driver; What attracts or deters investment? Lessons from investors in Europe and the U.S.; How can the public sector encourage investment and biotech companies take advantage of it? To register for this conference please click here.
European Conference on Companion Diagnostics
15 – 16 July 2015 in Berlin
This two-day conference is aimed at providing a European platform on development of companion diagnostics for a variety of stakeholders; to foster partnerships between pharmaceutical and diagnostic companies; to enable a dialogue with reimbursement authorities and regulatory institutions and to the exchange of best practices. Please find more information on the event held in Berlin here.
EUCOPE provides a platform for discussion for pharmaceutical entrepreneurs. On a regular basis owners and CEOs of pharmaceutical companies and associations discuss solutions to improve the quality of life for patients and to strengthen the competitiveness of the European pharmaceutical industry.
The legal framework for pharmaceutical markets is set largely by the EU institutions. An active role in the political debate on the EU level is therefore more important than ever before. The early perception of future markets and reliable regulatory circumstances are key aspects for entrepreneurial success.
Knowledge about this legal framework and the active discussion and participation on the EU level is therefore essential for pharmaceutical entrepreneurs in order to generate innovations.
EUCOPE understands itself as service provider for its members. The association provides its members with an early understanding about regulatory developments.
Current regulatory topics are:
- EMA Transparency Policy (Policy 0700)
- Clinical Trials Regulation (Regulation (EU) No 536/2014)
- EMA Fees Regulation (Regulation (EU) No 658/2014)
- Commission proposal Review IVD legislation
- Commission proposal Review Medical Devices legislation
A tight monitoring and comprehensive information about future market conditions are valuable assets for entrepreneurial decisions. Questions such as access to finance, market access and reliable reimbursement conditions are of crucial importance for pharmaceutical entrepreneurs.
Please find out more about EUCOPE under About us.
EUCOPE in the News
EUCOPE is in regular contact with the press on current developments in the EU and national pharma markets.
Please find some examples here.